Use of Gevokizumab in Patients with Behçet’s Disease Uveitis: An International, Randomized, Double-Masked, Placebo-Controlled Study and Open-Label Extension Study

Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial

(2016) Quan Dong Nguyen et al.   LANCET

Adalimumab in Patients with Active Noninfectious Uveitis

(2016) Glenn J. Jaffe et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of Gevokizumab in Patients with Behçet’s Disease Uveitis: Results of an Exploratory Phase 2 Study

(2016) Ilknur Tugal-Tutkun et al.   OCULAR IMMUNOLOGY AND INFLAMMATION

Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease

(2015) Luca Cantarini et al.   AUTOIMMUNITY REVIEWS

Efficacy and safety profile of anti-interleukin-1 treatment in Behçet’s disease: a multicenter retrospective study

(2015) Giacomo Emmi et al.   CLINICAL RHEUMATOLOGY

The immunogenetics of Behçet's disease: A comprehensive review

(2015) Masaki Takeuchi et al.   JOURNAL OF AUTOIMMUNITY

Ocular Involvement of Behçet’s Syndrome: a Comprehensive Review

(2014) Yilmaz Ozyazgan et al.   CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY

Anakinra treatment in drug-resistant Behcet’s disease: a case series

(2013) Luca Cantarini et al.   CLINICAL RHEUMATOLOGY

Therapy of Ocular Behçet Disease

(2013) Manfred Zierhut et al.   OCULAR IMMUNOLOGY AND INFLAMMATION

Differential Diagnosis of Behçet Uveitis

(2013) Ilknur Tugal-Tutkun et al.   OCULAR IMMUNOLOGY AND INFLAMMATION

Current and future treatments for Behçet’s uveitis: road to remission

(2013) Marina Mesquida et al.   INTERNATIONAL OPHTHALMOLOGY

Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet's disease: an open-label pilot study

(2011) Ahmet Gül et al.   ANNALS OF THE RHEUMATIC DISEASES

XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseases

(2011) Alexander M. Owyang et al.   mAbs

Kinetic Approach to Pathway Attenuation Using XOMA 052, a Regulatory Therapeutic Antibody That Modulates Interleukin-1β Activity

(2010) Marina K. Roell et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Interobserver Agreement in Scoring of Dual Fluorescein and ICG Inflammatory Angiographic Signs for the Grading of Posterior Segment Inflammation

(2010) Ilknur Tugal-Tutkun et al.   OCULAR IMMUNOLOGY AND INFLAMMATION

Anti-TNF Agents for Behçet's Disease: Analysis of Published Data on 369 Patients

(2010) Aikaterini Arida et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Behçet’s Syndrome

(2010) Yusuf Yazici et al.   Current Rheumatology Reports

EULAR recommendations for the management of Behcet disease

(2008) G Hatemi et al.   ANNALS OF THE RHEUMATIC DISEASES

Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease

(2008) G Hatemi et al.   ANNALS OF THE RHEUMATIC DISEASES

Scoring of dual fluorescein and ICG inflammatory angiographic signs for the grading of posterior segment inflammation (dual fluorescein and ICG angiographic scoring system for uveitis)

(2008) Ilknur Tugal-Tutkun et al.   INTERNATIONAL OPHTHALMOLOGY